Guidance
← 실적 발표
01
02
03
04 05 06
톤
A1
GILD
FY2026 Q2
상향
Gilead Sciences, Inc. 실적 발표
Buzzberg 분석
Gilead ups full-year HIV sales growth guidance to 9-10%
Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise.
Buzzberg 분석 Gilead ups full-year HIV sales growth guidance to 9-10% Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise. 전체 분석 보기분석 접기
Gilead reported strong Q2 2026 results driven by its HIV portfolio, Tredelvey, and Livdelzi, raising FY2026 guidance for total product sales. The company highlighted significant progress in its HIV pipeline with multiple long-acting options and a strong PrEP franchise, while also advancing its oncology portfolio through acquisitions and new approvals. Base business sales grew 10% year-over-year, with HIV sales up 12% driven by Biktarvy and the PrEP franchise.
- Yes2Go, a long-acting injectable PrEP, is established as the leading option with persistency rates over 70% and full-year sales target of approximately $1 billion.
- Tredelvy sales grew 26% year-over-year, driven by new approvals in first-line metastatic TNBC.
- Gilead raised its FY2026 total product sales guidance to $30.1-$30.4 billion and HIV growth guidance to 9-10%.
매출$7.803B+12% 전분기 대비
주당순이익(EPS)$-6.75보고값
잉여현금흐름$3.69B+52% 전분기 대비
자본지출$0.117B보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Demand
PrEP business reaches $4 billion annual run rate
Adoption
Yes2Go persistency at over 70% for reinjection
핵심 내용 3개 더 보기
Pipeline
BicLen FDA decision expected by August 27
Pipeline
ISLEN weekly oral HIV regimen targets 2027 launch
Clinical Data
GS8824 shows 61% response rate in ovarian cancer
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $7.803B | +12% 전분기 대비 |
| 주당순이익(EPS) | $-6.75 | 보고값 |
| 잉여현금흐름 | $3.69B | +52% 전분기 대비 |
| 자본지출 | $0.117B | 보고값 |
| 순이익 | $-2.021B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 매출 | FY2026 | $30.1B–$30.4B | $30.25B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management highlighted strong commercial execution, raised full-year HIV guidance, and pointed to multiple upcoming catalysts, reflecting a confident outlook.
아래에 언급된 기업 5개 모두 표시
기업발표 이후 수익률
파트너
PRGN
파트너
Dietmar Berger
The collaboration with PreGene is set to accelerate the development of Gilead's in vivo CAR-T platform with two investigator-sponsored studies, indicating a positive step for the platform.
근거
“And our collaboration with PreGene enables Speed2Clinic, where we will start exploring our updated in vivo platform in two investigator-sponsored studies later this year.”
파트너
Dietmar Berger
The HIV PrEP market itself is growing rapidly, and Gilead's overall PrEP business is now at a $4 billion annual run rate, significantly outpacing the market. — Gilead is expanding the entire PrEP market while gaining share, potentially impacting competitors like Merck's future prevention products.
근거
“highlights included oral presentations with a simultaneous publication in the New England Journal of Medicine on Gilead and Merck's once-weekly oral regimen, combining isletrovir plus lanacapivir, or ISLEN.”
투자 대상
투자 대상
Daniel O'Day
Gilead acquired full ownership of Arcelix's assets, indicating a positive view of its technology and a heightened focus to execute on its pipeline.
근거
“The completed acquisition of Arcelex has given us full ownership of a NitoCell enabling faster, more focused execution in multiple myeloma, as well as the D-domain binder platform for future opportunities”
투자 대상
Daniel O'Day
Gilead's acquisition of Tubulus brings an industry-leading ADC platform, signalling a positive outlook for its oncology pipeline and future growth.
근거
“The acquisition of Tubulus has now closed, providing Gilead with an industry-leading ADC platform and Promising Clinical Stage ADCs.”
OROM
투자 대상
Dietmar Berger
The acquisition of Oro medicines adds bispecific T-cell engager assets to Gilead's pipeline, indicating a diversification and strengthening of its oncology portfolio.
근거
“We expanded the breadth of our innovation engine through the acquisitions of Arcelix, Tubalys, and Oromedicins, adding differentiated and potentially best-in-class cell therapy, antibody drug conjugate, and bispecific T-cell engager assets.”
외부 신호
공급망 알파 · 1발표 이후 수익률
The HIV PrEP market itself is growing rapidly, and Gilead's overall PrEP business is now at a $4 billion annual run rate, significantly outpacing the market.
근거
“The U.S. PrEP market grew approximately 14% year-over-year, marking another quarter of double-digit percentage growth on an increasingly larger base of users. Gilead PrEP sales growth of over 100% has once again significantly outpaced the…”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 5개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.